- Home
- NUVB vs REX Comparison
NUVB vs REX Comparison
Compare NUVB & REX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- REX
- Stock Information
- Founded
- NUVB 2018
- REX 1980
- Country
- NUVB United States
- REX United States
- Employees
- NUVB N/A
- REX N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- REX Major Chemicals
- Sector
- NUVB Health Care
- REX Industrials
- Exchange
- NUVB Nasdaq
- REX Nasdaq
- Market Cap
- NUVB 850.3M
- REX 778.2M
- IPO Year
- NUVB N/A
- REX N/A
- Fundamental
- Price
- NUVB $2.62
- REX $45.09
- Analyst Decision
- NUVB Strong Buy
- REX Strong Buy
- Analyst Count
- NUVB 6
- REX 1
- Target Price
- NUVB $6.17
- REX $60.00
- AVG Volume (30 Days)
- NUVB 2.1M
- REX 92.7K
- Earning Date
- NUVB 11-06-2024
- REX 12-03-2024
- Dividend Yield
- NUVB N/A
- REX N/A
- EPS Growth
- NUVB N/A
- REX 166.93
- EPS
- NUVB N/A
- REX 3.92
- Revenue
- NUVB $2,162,000.00
- REX $718,079,000.00
- Revenue This Year
- NUVB N/A
- REX N/A
- Revenue Next Year
- NUVB N/A
- REX $13.53
- P/E Ratio
- NUVB N/A
- REX $11.22
- Revenue Growth
- NUVB N/A
- REX N/A
- 52 Week Low
- NUVB $1.22
- REX $36.40
- 52 Week High
- NUVB $4.16
- REX $60.79
- Technical
- Relative Strength Index (RSI)
- NUVB 49.69
- REX 46.82
- Support Level
- NUVB $2.44
- REX $43.57
- Resistance Level
- NUVB $3.07
- REX $46.97
- Average True Range (ATR)
- NUVB 0.17
- REX 1.54
- MACD
- NUVB -0.01
- REX -0.28
- Stochastic Oscillator
- NUVB 43.26
- REX 28.27
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.